Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Mr. Jeffrey  Frelick

Nazwa	Tytuł
Mr. Jeffrey Frelick	Chief Executive Officer & President
Dr. Shun'ichi Kuroda	Co-Founder & Member of Scientific Advisory Board
Ms. Deina H. Walsh	Chief Financial Officer

Bone Biologics Corporation

Bone Biologics Corporation Struktura zarządzania

Informacje o kierownictwie